OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2019.7330 OR-0-0-7330 Articles Prognostic significance of minichromosome maintenance mRNA expression in human lung adenocarcinoma LiShu 1 2 JiangZhou 2 LiYirun 3 XuYang 1 Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P.R. China Correspondence to: Professor Yang Xu, Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 9 Outpatient Building, 88 Jiefang Road, Hangzhou, Zhejiang 310009, P.R. China, E-mail: yxu@zju.edu.cn 12 2019 23 09 2019 42 6 2279 2292 20022019 09082019 Copyright: © Li et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The minichromosome maintenance (MCM) gene family plays an essential role in DNA replication and cell cycle progression. However, MCM gene expression has not been well-studied in lung adenocarcinoma (LUAD). In the present study, the expression, prognostic value and functions of MCMs in LUAD were investigated using several databases and bioinformatic tools, including Oncomine, GEPIA, cBioPortal, CancerSEA and Kaplan-Meier plotter. It was demonstrated that the mRNA expression of MCM2, MCM4 and MCM10 were significantly increased in patients with LUAD. High mRNA expression of MCM2-5, MCM8 and MCM10 were associated with poor overall survival and progression-free survival. High MCM4 expression was associated with adverse post-progression survival. In addition, the Human Protein Atlas database showed that MCM protein expression was consistent with the mRNA expression. These results demonstrate that MCM2, MCM4 and MCM10 are potential prognostic markers and therapeutic targets for LUAD.

 minichromosome maintenance family marker mRNA prognosis lung adenocarcinoma database Introduction

Lung cancer was the leading cause of cancer-related deaths worldwide in 2016 (1,2). Lung adenocarcinoma (LUAD), a histological type of non-small-cell lung cancer, accounts for a major proportion of this disease (3). In the last decade, the development of targeted therapy using tyrosine kinase inhibitors and crizotinib has led to improved clinical outcomes in LUAD patients with alterations in the epidermal growth factor receptor gene or fusion of echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase, respectively (4–7). More recently, immunotherapy has been developed and increasingly used in patients with lung cancer, including immune checkpoint inhibitors that target programmed cell death 1 ligand 1 (PD-L1)-expressing tumor cells by blocking PD-L1/PD-1 signaling (8,9). Despite recent advances in targeted therapy and immunotherapy, the prognosis of LUAD remains poor (10). It has become a research trend to explore novel molecular biomarkers or therapeutic targets in the era of precision medicine (11). In fact, databases based on large-scale, genome-wide association studies have facilitated the discovery of new biomarkers for cancer management (12).

The minichromosome maintenance (MCM) family consists of 8 highly conserved members, including MCM2-7, MCM8 and MCM10 (13). MCM2-7 form the MCM complex, a hexamer that binds to DNA and functions in the initiation of DNA replication (14,15). MCM8 is unique in that it serves as a DNA helicase during replication elongation, but not initiation (16). MCM10 helps to regulate DNA replication elongation (17). In line with their essential roles in DNA replication, MCM genes have become valuable biomarkers for cancer diagnosis and prognosis prediction (18–21). Previous studies have shown that MCM2, MCM4 and MCM7 regulate cell proliferation in non-small cell lung cancer (NSCLC) (22–24). However, the functions of other MCM family members remain unclear, and a comprehensive mRNA profiling of MCM family members in lung cancer has not been performed. In the present study, database research and bioinformatic analysis were performed to determine the prognostic significance of MCM mRNA expression in patients with lung cancer.

 Materials and methods <sec> <title>Ethics statement

This study was performed in accordance with standard guidelines, and was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang, China). The datasets were retrieved from published literature in which informed consent was obtained from patients.

 Oncomine analysis

The Oncomine database (www.oncomine.org) is a bioinformatics tool for collecting, standardizing, analyzing and delivering cancer transcriptome data to the biomedical research community. It was used to compare the transcription levels of MCMs between cancer specimens and paracarcinoma tissue. In Oncomine, Student's t-test is generated for two class differential expression analyses (25). In the present study, P<0.01 and an absolute fold-change ≥1.5 were selected as the cut off values to analyze the gene expression chart of each MCM family member.

 Gene expression profiling interactive analysis (GEPIA) database

GEPIA (http://gepia.cancer-pku.cn/) is a web tool that provides fast and customizable functionalities based on data from The Cancer Genome Atlas (TCGA; http://tcga-data.nci.nih.gov/tcga/) and the Genotype-Tissue Expression project (GTEx; http://www.gtexportal.org/home/index.html). Differential analysis was performed using one-way ANOVA, using disease state or tumor stage as the variable for calculating differential expression (26). In the current study, GEPIA was used to represent the differential expression of MCMs graphically between LUAD and paracarcinoma tissues and the association between the expression of MCMs and tumor stages in patients with LUAD (27).

 The human protein atlas database

The Human Protein Atlas (https://www.proteinatlas.org/) is a database of immunohistochemistry (IHC)-based protein expression profiles in normal tissue, cancer and cell lines (28). IHC images of MCM protein expression in clinical specimens of patients with LUAD and paracarcinoma tissues were obtained from the Human Protein Atlas database.

 Kaplan-meier plotter

The Kaplan-Meier Plotter tool (www.kmplot.com) includes survival information of 866 patients with LUAD. The prognostic value of MCM expression was assessed by overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS), using the hazard ratio (HR), 95% confidence intervals (CI) and log-rank P-value. In the analysis, patient samples were split into high expression group and low expression group based on the median mRNA levels of the MCMs. The prognostic value of a gene was assessed by univariate Cox regression analysis (29). JetSet scores were used to select a single representative probe set for each gene (30). In the current study, only the probe sets with best JetSet scores for MCMs were selected to produce Kaplan-Meier plots. The one-to-one matches between MCM genes and probe sets, identified by Affymetrix IDs, were as follows: MCM2 and 272107_s_at; MCM3 and 201555_at; MCM4 and 222036_s_at; MCM5 and 216237_s_at; MCM6 and 238977_at; MCM7 and 208795_s_at; MCM8 and 224320_s_at; and MCM10 and 223570_at. The relevant concepts are defined as follows: OS, time from diagnosis to death; PFS, time from diagnosis to tumor progression; PPS, time from progression to death; HR>1, worse survival prognosis for the group with high mRNA expression; HR<1, unfavorable survival prognosis in the low mRNA expression group; 95% CI does not cross 1, mRNA expression is associated with survival rate. As not all gene expression levels were available in all patients and only the JetSet probes were included in the study, the sample sizes vary for each survival analysis.

 cBioPortal for cancer genomics (cBioPortal) dataset

cBioPortal (http://cbioportal.org) is based on other authoritative databases, including the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and TCGA database. cBioPortal is a web resource for exploring, visualizing and analyzing multidimensional cancer genomics data. The genomic profile of each gene includes mutations, putative copy-number alterations and mRNA expression z-scores. The z score for each gene is the normalized expression of mRNA using RNA-Seq by expectation maximization count estimates method. The co-expression of each gene pair was performed by Fisher's exact test (31) and the network was constructed according to the correlation.

 Cancer SEA

CancerSEA (http://biocc.hrbmu.edu.cn/CancerSEA/) is a dedicated database for comprehensively exploring distinct functional states of cancer cells at the single-cell level. The cancer-related single cell RNA-seq (scRNA-seq) datasets for human samples in CancerSEA were collected from the Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra), the GEO database and ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). For each cancer-related scRNA-seq dataset, the original paper was read and the corresponding metadata was extracted, including the cancer types and sources, including patient-derived xenograft (PDX) and circulating tumor cell (CTC). Thus, CancerSEA contained the cancer single-cell functional state atlas of 41,900 cancer single cells from 25 cancer types. LUAD chips and PDX are numbered with Exp and LC-PT as the headers, respectively. For each single-cell dataset derived from PDX and CTC tumor tissue, significant correlations between gene expression and functional state activities were analyzed using Spearman's rank correlation test with false discovery rate correction for multiple comparisons (32). In the present study, CancerSEA was used for the functional analysis of MCMs.

 Results <sec> <title>Transcriptional levels of MCMs in patients with LUAD

The MCM transcriptional levels in cancers were compared with those in paracarcinoma tissues using the Oncomine database. As presented in Fig. 1, MCMs were generally overexpressed in most tumors. In lung cancer, all MCM members were upregulated in cancer tissues, except MCM6, which was downregulated in one dataset, which may be due to the limited numbers of samples. MCM mRNA expression in LUAD and paracarcinoma tissues are summarized in Table I. The mRNA levels of all MCM members were significantly increased in LUAD tissues. MCM2 overexpression was present in 8 databases (33–39), followed by MCM4 in 7 datasets (33–37,39,40). MCM10 is the most upregulated member with a fold increase of 6.446 in the dataset from a study by Hou et al (33).

 MCM mRNA expression is associated with pathological stages of LUAD

As with Oncomine, GEPIA analysis indicated that expression of MCM2-7, MCM8 and MCM10 was higher in LUAD than in lung tissues (Fig. 2), although statistically significant differences were observed for MCM2 (Fig. 2A), MCM4 (Fig. 2C) and MCM10 (Fig. 2H) only. The association between MCM expression and LUAD pathological stage was then investigated. As presented in Fig. 3, the mRNA levels of MCM2 (P=0.0407; Fig. 3A), MCM4 (P=0.00101; Fig. 3C), MCM6 (P=0.0096; Fig. 3E), MCM7 (P=0.00595; Fig. 3F) and MCM 10 (P=0.00598; Fig. 3H) significantly different between the tumor stages I to IV. Similar trends occurred for MCM3 (P=0.0605; Fig. 3B) and MCM5 (P=0.0957; Fig. 3D). However, there was no association between MCM8 (P=0.231; Fig. 3G) and tumor stage.

 Protein expression levels of MCMs in patients with LUAD

To examine whether MCM protein was also differentially expressed in LUAD tissues, immunohistochemical staining images for the MCM proteins in LUAD and paracarcinoma tissues were obtained from the Human Protein Atlas database (Fig. 4). Consistent with RNA expression data, the results demonstrated that MCM2, MCM5, MCM6 and MCM7 protein levels were higher in LUAD tissue compared with normal tissue, whereas MCM3, MCM4 and MCM10 proteins were only slightly increased in LUAD tissue.

 The prognostic significance of MCMs in patients with LUAD

Using the Kaplan-Meier plotter, the prognostic significance of the mRNA expression of MCMs in patients with LUAD was determined. Seven MCM members were significantly associated with reduced OS in patients with LUAD (Fig. 5A). Survival curves are presented in Fig. 5B-I. High expression of MCM2 (Fig. 5B; HR, 1.33; 95% CI, 1.05–1.67; P=0.018), MCM3 (Fig. 5C; HR, 2.20; 95% CI, 1.72–2.82; P=1.1×10−10), MCM4 (Fig. 5D; HR, 2.27; 95% CI, 1.78–2.90; P=1.1×10−11), MCM5 (Fig. 5E; HR, 1.34; 95% CI, 1.06–1.79; P=0.014), MCM7 (Fig. 5G; HR, 1.29; 95% CI, 1.02–1.63; P=0.031), MCM8 (Fig. 5H; HR, 1.34; 95% CI, 1.05–1.71; P=0.019) and MCM10 (Fig. 5I; HR, 1.29; 95% CI, 1.02–1.63; P=0.031) were associated with worse OS, while MCM6 was not associated with altered OS (Fig. 5F; HR, 1.08; 95% CI, 0.85–1.37; P=0.530).

Similarly, high expression of MCM2 (Fig. 6B; HR, 1.62; 95% CI, 1.18–2.22; P=0.003), MCM3 (Fig. 6C; HR, 1.39; 95% CI, 1.02–1.90; P=0.037), MCM4 (Fig. 6D; HR, 2.38; 95% CI, 1.72–3.31; P=8.3×10−8), MCM5 (Fig. 6E; HR, 1.42; 95% CI, 1.04–1.95; P=0.027), MCM8 (Fig. 6H; HR, 1.44; 95% CI, 1.04–1.99; P=0.027) and MCM10 (Fig. 6I; HR, 1.94; 95% CI, 1.40–2.71; P=6.5×10−5) was significantly associated with reduced PFS. Additionally, high MCM4 mRNA expression also indicated adverse PPS (Fig. 6D; HR, 1.62; 95% CI, 1.01–2.59; P=0.043). Other MCMs were not associated with PFS or PPS (Figs. 6 and 7).

 MCM expression changes in LUAD and the network within each MCM or with other genes

With the cBioPortal online tool, the alterations, correlations and networks of MCMs in LUAD were analyzed. Of the LUAD samples, 39% had altered MCMs, and the most common genetic change was gene amplification (Fig. 8A). The distribution of genetic alterations for individual MCMs indicated that nearly 15% of LUAD cases had MCM4 amplification (Fig. 8B). Significant and positive correlations were observed between the MCMs (Fig. 8C). Among them, MCM2 and MCM6 had the highest positive correlation with a Spearman's correlation coefficient of 0.848. MCM10 exhibited the tightest association with all other MCMs, with a median Spearman's correlation coefficient of 0.771. Next, the network for MCMs and the genes frequently altered with MCMs was constructed (Fig. 8D). The majority of the genes frequently altered with MCMs were cell cycle-related or involved in DNA damage/repair, such as ATM serine/threonine kinase, RAD1 checkpoint DNA exonuclease, cyclin dependent kinase 1, cyclin A1 and replication factor C subunit 5, suggesting that the MCM family is critical for maintenance of genome integrity.

 The functions of MCMs in single LUAD cell

Heterogeneity between cancer cells poses a major challenge for cancer diagnosis and treatment. Single-cell sequencing technology provides an unprecedented opportunity to accurately decipher the functional states of cancer cells at a single-cell resolution.

Using CancerSEA, the functions of MCMs in single LUAD cells were explored. MCM function was found to be mainly related to cell cycle, DNA damage or DNA repair (Fig. 9A). Kim (Exp0066) showed high expression of the MCM family was positively correlated with DNA repair, cell cycle, DNA damage and proliferation (Spearman's coefficients, 0.60, 0.56, 0.50 and 0.32, respectively; P<0.001) (41). Correlation analysis also revealed a negative correlation of MCM expression and quiescence, inflammation, hypoxia and differentiation (Spearman's coefficient, −0.41, −0.32, −0.31 and −0.31, respectively; P<0.001) (Fig. 9B). Similar results were observed in patient-derived xenograft (LC-PT-45) (41) (Fig. 9C).

 Discussion

Uncontrolled cancer cell proliferation is usually accompanied by dysregulated DNA replication, and chemotherapeutic agents targeting replication machinery have been widely used for cancer treatment (42). MCMs, essential molecules in the initiation and elongation of DNA replication, are considered to be useful indicators of cell proliferation, and MCM alterations are more frequent in neoplastic cells than in non-neoplastic cells (43). Moreover, MCM proteins are expressed in rapidly dividing cells, but not in quiescent, aging or differentiated cells (44). Therefore, MCMs may have potential clinical application as markers for cancer screening. However, a comprehensive bioinformatics analysis of MCMs in LUAD has yet to be performed. To the best of our knowledge, this is the first study to explore the mRNA expression levels of the MCM family and their prognostic relevance for predicting OS, PFS and PPS in LUAD. Our findings highlight potential roles for MCMs in diagnosis and risk stratification in patients with LUAD.

MCM2 is the most studied MCM member that is upregulated in LUAD, and MCM2 dysregulation is associated with cell proliferation, cell cycle progression and migration (45). A significant correlation between MCM2 mRNA expression and LUAD stages was previously observed, and MCM2 was demonstrated to be the therapeutic target of lovastatin for NSCLC treatment (46). Additionally, Veena et al (47) reported that the MCM2 was present in lung tissues and in sputum, which is more accessible for MCM2 detection. However, the association between MCM2 expression and treatment outcomes of patients with NSCLC remains controversial (44,48–50). In the present study, analysis using the Oncomine and GEPIA bioinformatics tools revealed that MCM2 expression was higher in LUAD tissues compared with that in normal tissues, and this finding was consistent with immunohistochemical staining for MCM2 in the Human Protein Atlas. Using the Kaplan-Meier Plotter, elevated MCM2 mRNA was found to be significantly associated with reduced OS and PFS in patients with LUAD.

MCM3 had been found to be differentially expressed in LUAD and adjacent normal tissue samples (51,52); however, the role of MCM3 in NSCLC was unclear. Zhang et al (53) found that the PI3K inhibitor, LY294002, inhibited MCM3 expression in NSCLC cells, indicating that MCM3 is involved in the PI3K-Akt pathway. In the present study, MCM3 upregulation was also observed in LUAD tissues, and high MCM3 expression was associated with poor OS and PFS, but not PPS in patients with LUAD.

MCM4 overexpression is an oncogenic event in LUAD (54). A study by Kikuchi et al (55) showed that high MCM4 expression was associated with clinicopathological features of LUAD, but was not associated with survival. However, in the present study, high expression of MCM4 was associated with worse OS, PFS and PPS.

MCM5 is upregulated in lung squamous cell carcinoma, and patients with high MCM5 expression have reduced OS (43). In the current study, MCM5 was also found to be elevated in LUAD and was associated with adverse OS and PFS.

MCM6, together with Ki-67 and HuR, an RNA binding protein, were associated with poor prognosis in NSCLC (44,56). However, no association was found between MCM6 expression and patient outcome in the current study.

MCM7 is involved in proliferation and signal transduction of the receptor of activated protein C kinase 1/Akt pathway (57). Moreover, pre-clinical research based on NSCLC cell lines showed that MCM7 and its targets, a cluster of miR-25, miR-93 and miR-106b, elicited oncogenic activity in lung cancer (58). MCM7 expression was also associated with worse prognosis in patients with NSCLC (59,60). In the present study, high MCM7 expression was suggested to be a predictor for poor OS and PFS.

Little is known about the role of MCM8 and MCM10 in lung cancer. MCM8 is expressed in tissue with a high percentage of proliferating cells, such as lung and liver (13,16). MCM10 promotes cell proliferation (17), is associated with poor prognosis and is considered to be a potential therapeutic target in breast and prostate cancer (61). In the current study, MCM8 mRNA, but not protein expression was found to be is higher in tumor compared with normal tissues. Similarly, MCM10 was also found to be overexpressed in LUAD. However, neither MCM8 nor MCM10 were associated with the OS of patients with LUAD.

MCMs have frequently been compared with Ki-67, a well-established marker of cell proliferation (62). In adrenocortical cancer, MCM3 and MCM7 share a similar staining pattern with Ki-67 in benign and malignant tissues (63). MCM4 and MCM7 are more sensitive markers than Ki-67 for the detection of esophageal cancer (64). Furthermore, MCM5 and MCM2, but not Ki-67, have been associated with poor prognosis in gastric cancer and NSCLC (65,66). As a marker of G1-phase arrest in mantle cell lymphoma, MCM6 is superior to other clinical parameters, including Ki-67 (48). MCM2 expression is higher than Ki-67 in megakaryocytes, suggesting that MCM2 may be a more sensitive marker for some hematological diseases (67). In tissue sections, MCM proteins are more highly expressed than Ki-67 in quiescent cells (68,69). Taken together, these results suggest that the MCM family may be better proliferation markers than Ki-67 for cancer diagnosis and risk stratification.

In the present study, the expression and prognostic significance of MCMs in LUAD was analyzed. MCM2-6 were found to be upregulated and associated with LUAD prognosis. Notably, high expression of MCM2-5 was associated with reduced OS and PFS. MCM7 expression was also associated with poor OS, and MCM4 predicted worse PPS. As MCM expression was found to be consistent at the mRNA and protein level, analysis of mRNA in patient samples may be preferred as it is easier to analyze. Thus, transcriptional detection of MCM members may provide robust biomarkers to improve patient survival and prognosis prediction in LUAD. As all data and results in this study are based on bioinformatic analysis, further studies are required to determine the role of MCMs in vitro and in vivo.

 Acknowledgments

Not applicable.

 Funding

This study was supported by the National Natural Science Foundation of China (grant no. 81572920), the Natural Science Foundation of Zhejiang Province of China (grant no. LY15H160038) and the National Basic Research Program of China (grant no. 2013CB911303).

 Availability of data and materials

The datasets analyzed during the current study are publicly available from the following online databases: Oncomine database (www.oncomine.org); GEPIA database (http://gepia.cancer-pku.cn/); Kaplan-Meier Plotter (www.kmplot.com); The Human Protein Atlas (https://www.proteinatlas.org/); cBioPortal (http://cbioportal.org); GEO (http://www.ncbi.nlm.nih.gov/geo/); TCGA (https://tcga-data.nci.nih.gov/tcga/); CancerSEA (http://biocc.hrbmu.edu.cn/CancerSEA/).

 Authors' contributions

SL and YX designed the study. SL, ZJ and YL acquired the data, performed data analysis and interpretation. ZJ and YL drafted the manuscript, and YX and SL critically revised it for important intellectual content. All authors gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

 Ethics approval and consent to participate

This study was performed in accordance with standard guidelines and was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References MaruthappuMWatkinsJNoorAMWilliamsCAliRSullivanRZeltnerTAtunREconomic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: A longitudinal analysisLancet388684695201610.1016/S0140-6736(16)00577-827236345 MillerKDSiegelRLLinCCMariottoABKramerJLRowlandJHSteinKDAlteriRJemalACancer treatment and survivorship statistics, 2016CA Cancer J Clin66271289201610.3322/caac.2134927253694 RosellRBivonaTGKarachaliouNGenetics and biomarkers in personalisation of lung cancer treatmentLancet382720731201310.1016/S0140-6736(13)61715-823972815 TsaoMSSakuradaACutzJCZhuCQKamel-ReidSSquireJLorimerIZhangTLiuNDaneshmandMErlotinib in lung cancer-molecular and clinical predictors of outcomeN Engl J Med353133144200510.1056/NEJMoa05073616014883 PaezJGJännePALeeJCTracySGreulichHGabrielSHermanPKayeFJLindemanNBoggonTJEGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapyScience30414971500200410.1126/science.109931415118125 MitsudomiTYatabeYMutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancerCancer Sci9818171824200710.1111/j.1349-7006.2007.00607.x17888036 SodaMChoiYLEnomotoMTakadaSYamashitaYIshikawaSFujiwaraSWatanabeHKurashinaKHatanakaHIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature448561566200710.1038/nature0594517625570 LastwikaKJWilsonWIIILiQKNorrisJXuHGhazarianSRKitagawaHKawabataSTaubeJMYaoSControl of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancerCancer Res76227238201610.1158/0008-5472.CAN-14-336226637667 FacchinettiFMarabelleARossiGSoriaJCBesseBTiseoMMoving immune checkpoint blockade in thoracic tumors beyond NSCLCJ Thorac Oncol1118191836201610.1016/j.jtho.2016.05.02727288978 TravisWDBrambillaEBurkeAPMarxANicholsonAGIntroduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heartJ Thorac Oncol1012401242201510.1097/JTO.000000000000066326291007 TsaoASScagliottiGVBunnPAJrCarboneDPWarrenGWBaiCde KoningHJYousaf-KhanAUMcWilliamsATsaoMSScientific advances in lung cancer 2015J Thorac Oncol11613638201610.1016/j.jtho.2016.03.01227013409 DirksRAStunnenbergHGMarksHGenome-wide epigenomic profiling for biomarker discoveryClin Epigenetics8122201610.1186/s13148-016-0284-4278958065117701 JohnsonEMKinoshitaYDanielDCA new member of the MCM protein family encoded by the human MCM8 gene, located contrapodal to GCD10 at chromosome band 20p12.3–13Nucleic Acids Res3129152925200310.1093/nar/gkg39512771218156728 BikKTMCM proteins in DNA replicationAnnu Rev Biochem68649686199910.1146/annurev.biochem.68.1.64910872463 RemusDBeuronFTolunGGriffithJDMorrisEPDiffleyJFConcerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensingCell139719730200910.1016/j.cell.2009.10.015198961822804858 MaioranoDCuvierODanisEMéchaliMMCM8 is an MCM2-7-related protein that functions as a DNA helicase during replication elongation and not initiationCell120315328200510.1016/j.cell.2004.12.01015707891 LõokeMMaloneyMFBellSPMcm10 regulates DNA replication elongation by stimulating the CMG replicative helicaseGenes Dev31291305201710.1101/gad.291336.116282705175358725 HuaCZhaoGLiYBieLMinichromosome maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomasBMC Cancer14526201410.1186/1471-2407-14-526250469754223428 PengYPZhuYYinLDZhangJJGuoSFuYMiaoYWeiJSThe expressionand prognostic roles of MCMs in pancreatic cancerPLoS One11e0164150201610.1371/journal.pone.0164150276950575047525 KwokHFZhangSDMcCruddenCMYuenHFTingKPWenQKhooUSChanKYPrognostic signifcance of minichromosome maintenance proteins in breast cancerAm J Cancer Res552712014256289204300722 LiaoXLiuXYangCWangXYuTHanCHuangKZhuGSuHQinWDistinct diagnostic and prognostic values of minichromosome maintenance gene expression in patients with hepatocellular carcinomaJ Cancer923572373201810.7150/jca.25221300268326036720 WerynskaBPulaBMuszczynska-BernhardBPiotrowskaAJethonAPodhorska-OkolowMDziegielPJankowskaRCorrelation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancerAnticancer Res3128332839201121868526 WuWWangXShanCLiYLiFMinichromosome maintenance protein 2 correlates with the malignant status and regulates proliferation and cell cycle in lung squamous cell carcinomaOnco Targets Ther1150255034201810.2147/OTT.S169002301744406109654 FujiokaSShomoriKNishiharaKYamagaKNosakaKArakiKHarukiTTaniguchiYNakamuraHItoHExpression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implicationLung Cancer65223229200910.1016/j.lungcan.2008.11.00719144445 RhodesDRKalyana-SundaramSMahavisnoVVaramballyRYuJBriggsBBBarretteTRAnstetMJKincead-BealCKulkarniPOncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profilesNeoplasia9166180200710.1593/neo.07112173567131813932 TangZLiCKangBGaoGLiCZhangZGEPIA: A web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Res45(W1)W98W102201710.1093/nar/gkx247284071455570223 ChanskyKDetterbeckFCNicholsonAGRuschVWVallièresEGroomePKennedyCKrasnikMPeakeMShemanskiLThe IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancerJ Thorac Oncol1211091121201710.1016/j.jtho.2017.04.01128461257 PonténFJirströmKUhlenMThe human protein atlas-a tool for pathologyJ Pathol216387393200810.1002/path.244018853439 GyőrffyBSurowiakPBudcziesJLánczkyAOnline survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancerPLoS One8e82241201310.1371/journal.pone.0082241243675073867325 LiQBirkbakNJGyorffyBSzallasiZEklundACJetset: Selecting the optimal microarray probe set to represent a geneBMC Bioinformatics12474201110.1186/1471-2105-12-474221720143266307 GaoJAksoyBADogrusozUDresdnerGGrossBSumerSOSunYJacobsenASinhaRLarssonEIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal6pl1201310.1126/scisignal.2004088235502104160307 YuanHYanMZhangGLiuWDengCLiaoGXuLLuoTYanHLongZCancerSEA: A cancer single-cell state atlasNucleic Acids Res47D1D900D908201910.1093/nar/gky93930329142 HouJAertsJden HamerBvan IjckenWden BakkerMRiegmanPvan der LeestCvan der SpekPFoekens J HoogstedenHCGene expression-based classification of non-small cell lung carcinomas and survival predictionPLoS One5e10312201010.1371/journal.pone.0010312204219872858668 SelamatSAChungBSGirardLZhangWZhangYCampanMSiegmundKDKossMNHagenJALamWLGenome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expressionGenome Res2211971211201210.1101/gr.132662.111226138423396362 SuLJChangCWWuYCChenKCLinCJLiangSCLinCHWhang-PengJHsuSLChenCHHuangCYSelection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling schemeBMC Genomics8140201710.1186/1471-2164-8-140 OkayamaHKohnoTIshiiYShimadaYShiraishiKIwakawaRFurutaKTsutaKShibataTYamamotoSIdentification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomasCancer Res72100111201210.1158/0008-5472.CAN-11-140322080568 LandiMTDrachevaTRotunnoMFigueroaJDLiuHDasguptaAMannFEFukuokaJHamesMBergenAWGene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survivalPLoS One3e1651200810.1371/journal.pone.0001651182971322249927 StearmanRSDwyer-NieldLZerbeLBlaineSAChanZBunnPAJrJohnsonGLHirschFRMerrickDTFranklinWAAnalysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine modelAm J Pathol16717631775200510.1016/S0002-9440(10)61257-6163144861613183 BeerDGKardiaSLHuangCCGiordanoTJLevinAMMisekDELinLChenGGharibTGThomasDGGene-expression profiles predict survival of patients with lung adenocarcinomaNat Med8816824200210.1038/nm73312118244 GarberMETroyanskayaOGSchluensKPetersenSThaeslerZPacyna-GengelbachMvan de RijnMRosenGDPerouCMWhyteRIDiversity of gene expression in adenocarcinoma of the lungProc Natl Acad Sci USA981378413789200110.1073/pnas.24150079811707590 KimKTLeeHWLeeHOKimSCSeoYJChungWEumHHNamDHKimJJooKMParkWYSingle-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cellsGenome Biol16127201510.1186/s13059-015-0692-3260843354506401 SimonNESchwachaAThe Mcm2-7 replicative helicase: A promising chemotherapeutic targetBiomed Res Int2014549719201410.1155/2014/549719252431494163376 LiuYZWangBSJiangYYCaoJHaoJJZhangYXuXCaiYWangMRMCMs expression in lung cancer: Implication of prognostic significanceJ Cancer836413647201710.7150/jca.20777291519505688916 TachibanaKEGonzalezMAColemanNCell-cycle-dependent regulation of DNA replication and its relevance to cancer pathologyJ Pathol205123129200510.1002/path.170815643673 CheungCHYHsuCLChenKPChongST1WuCHHuangHCJuanHFMCM2-regulated functional networks in lung cancer by multi-dimensional proteomic approachSci Rep713302201710.1038/s41598-017-13440-x290384885643318 ZhangXTengYYangFWangMHongXYeLGGaoYNChenGYMCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomasOncol Rep3325992605201510.3892/or.2015.382225738322 VeenaVSRajanKSarithaVNPreethi SaraGChandramohanKJayasreeKTharaSSujathanKDNA replication licensing proteins for early detection of lung cancerAsian Pac J Cancer Prev18304130472017291722775773789 YangJRamnathNMoysichKBAschHLSwedeHAlrawiSJHubermanJGeradtsJBrooksJSTanDPrognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancerBMC Cancer6203200610.1186/1471-2407-6-203168823451555597 KadaraHLacroixLBehrensCSolisLGuXLeeJJTaharaELotanDHongWKWistubaIILotanRIdentification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis systemCancer Prev Res (Phila)2702711200910.1158/1940-6207.CAPR-09-0084196384913382104 RamnathNHernandezFJTanDFHubermanJANatarajanNBeckAFHylandATodorovITBrooksJSBeplerGMCM2 is an independent predictor of survival in patients with non-small-cell lung cancerJ Clin Oncol1942594266200110.1200/JCO.2001.19.22.425911709570 HaSAShinSMNamkoongHLeeHChoGWHurSYKimTEKimJWCancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesisClin Cancer Res1083868395200410.1158/1078-0432.CCR-04-102915623617 XuHMaJWuJChenLSunFQuCZhengDXuSGene expression profiling analysis of lung adenocarcinomaBraz J Med Biol Res49piiS0100879X20160003006012016 ZhangCElkahlounAGLiaoHDelaneySSaberBMorrowBPrendergastGCHollanderMCGillsJJDennisPAExpression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cellsMol Cancer Ther1011371148201110.1158/1535-7163.MCT-10-1028215512613132820 YiJWeiXLiXWanLDongJWangRA genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancerAnticancer Drugs291018201810.1097/CAD.000000000000057129084003 KikuchiJKinoshitaIShimizuYKikuchiETakedaKAburataniHOizumiSKonishiJKagaKMatsunoYMinichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancerLung Cancer72229237201110.1016/j.lungcan.2010.08.02020884074 VigourouxCCasseJMBattaglia-HsuSFBrochinLLucAParisCLacommeSGueantJLVignaudJMGauchotteGMethyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinomaLung Cancer89189196201510.1016/j.lungcan.2015.05.00826013954 FeiLMaYZhangMLiuXLuoYWangCZhangHZhangWHanYRACK1 promotes lung cancer cell growth via an MCM7/RACK1/Akt signaling complexOncotarget84050140513201710.18632/oncotarget.17120284654885522230 Lo SardoFForcatoMSacconiACapaciVZanconatoFDi AgostinoSDel SalGPandolfiPPStranoSBicciatoSBlandinoGMCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancerCarcinogenesis386475201710.1093/carcin/bgw11027797825 ToyokawaGMasudaKDaigoYChoHSYoshimatsuMTakawaMHayamiSMaejimaKChinoMFieldHIMinichromosome Maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancerMol Cancer1065201110.1186/1476-4598-10-65216196713125391 LiuYZJiangYYHaoJJLuSSZhangTTShangLCaoJSongXWangBSCaiYPrognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC)Lung Cancer77176182201210.1016/j.lungcan.2012.03.00122456526 CuiFHuJNingSTanJTangHOverexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancerProstate7812991310201810.1002/pros.23703300951716282949 BrownDCGatterKCKi67 protein: The immaculate deception?Histopathology40211200210.1046/j.1365-2559.2002.01343.x11903593 AporowiczMCzopnikPKubickaEPiotrowskaADziegielPBolanowskiMDomoslawskiPMinichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumorsAnticancer Res3911511159201910.21873/anticanres.1322430842144 ChoyBLaLondeAQueJWuTZhouZMCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesionsHum Pathol57126135201610.1016/j.humpath.2016.07.013274767765250507 GiaginisCGiaginiATsourouflisGGatzidouEAgapitosEKouraklisGTheocharisSMCM-2 and MCM-5 expression in gastric adenocarcinoma: Clinical significance and comparison with Ki-67 proliferative markerDig Dis Sci56777785201110.1007/s10620-010-1348-520694513 SchraderCJanssenDKlapperWSiebmannJUMeusersPBrittingerGKnebaMTiemannMParwareschRMinichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphomaBr J Cancer93939945200510.1038/sj.bjc.6602795161895222361659 LampertIAHorncastleDDilworthSRobertsIAlisonMRNareshKNThe expression of minichromosome maintenance protein-2 in normal and abnormal megakaryocytes and comparison with the proliferative marker Ki-67Br J Haematol131490494200510.1111/j.1365-2141.2005.05801.x16281941 EndlEKauschIBaackMKnippersRGerdesJScholzenTThe expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cellsJ Pathol195457462200110.1002/path.97811745678 ChatrathPScottISMorrisLSDaviesRJRushbrookSMBirdKVowlerSLGrantJWSaeedITHowardDAberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesionsBr J Cancer8910481054200310.1038/sj.bjc.6601234129664242376943

Expression of MCMs in cancer vs. normal tissues from the Oncomine database. Color is determined by the highest gene rank percentile genes based on log fold-change; red indicates upregulation and blue represents downregulation. The values within each cell represent the number of databases that met the filter criteria for differently expressed MCMs in cancer and normal tissues. MCM, minichromosome maintenance.

Expression of MCMs in lung adenocarcinoma and normal tissues analyzed using GEPIA. (A) MCM2, (B) MCM3, (C) MCM4, (D) MCM5, (E) MCM6, (F) MCM7, (G) MCM8 and (H) MCM10. In the box plots, the thick line in the middle represents the median, and the upper and lower limits of the box represent the third and first quartile respectively. The top and bottom of the error bars represent the maximum and minimum values of data, respectively; outliers were considered to be >1.5 quartile spacing, and were excluded. *P<0.05. MCM, minichromosome maintenance; T, tumor; N, normal; num, number.

Association of mRNA expression of MCMs and tumor stages in patients with lung adenocarcinoma analyzed using GEPIA. (A) MCM2, (B) MCM3, (C) MCM4, (D) MCM5, (E) MCM6, (F) MCM7, (G) MCM8 and (H) MCM10. In the violin plots, the white dots represent the median; the black bars represent the 95% confidence intervals; the black lines represent the interquartile range; and the width of the red shapes represent the density of distribution. MCM, minichromosome maintenance. F-value, the statistical value of F test; Pr (>F), P-value.

Immunohistochemical staining for protein expression of MCMs in tissues from patients with LUAD and normal tissues, obtained from The Human Protein Atlas. MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

OS of LUAD patients with high and low mRNA expression of MCM, analyzed using the Kaplan-Meier Plotter tool. (A) Prognostic HRs of individual MCM members in LUAD; error bars represent the 95% confidence intervals. (B-I) OS curves of MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, MCM8 and MCM10 plotted for all patients (n=720). OS, overall survival; HR, hazard ratio; MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

PFS in LUAD patients with high and low mRNA expression of MCM, analyzed using the Kaplan-Meier Plotter tool. (A) Prognostic HRs of individual MCM members in LUAD; error bars represent the 95% confidence intervals. (B-I) PFS curves of MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, MCM8 and MCM10 plotted for all patients (n=461). PFS, progression-free survival; HR, hazard ratio; MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

PPS of LUAD patients with high and low mRNA expression of MCM, analyzed using the Kaplan-Meier Plotter tool. (A) Prognostic HRs of individual MCM members in LUAD; error bars represent the 95% confidence intervals. (B-I) PPS curves of MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, MCM8 and MCM10 plotted for all patients (n=125). PPS, post-progression survival; HR, hazard ratio; MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

Analysis of MCM expression and mutation type and frequency in LUAD tissues using cBioPortal. (A) Summary of frequencies of alterations of MCMs in LUAD. (B) Genetic alterations of each MCM family member in LUAD patients. (C) Correlation between expression of MCM family members; Spearman's correlation coefficients are presented. Only those with a P<0.05 were included in the image. (D) Network of MCM genes and the genes frequently altered with MCMs. MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

Functional analysis of MCMs with CancerSEA. (A) Functional relevance of MCMs in patients with LUAD. Bubble size represents the average correlation strength; red indicates a positive correlation and blue indicates a negative correlation. Detailed functional correlations in (B) LUAD chip and (C) in PXD model. **P<0.01 and ***P<0.001. MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.

Comparison of mRNA expression of MCMs in lung adenocarcinoma and normal lung tissues from the Oncomine database.

Gene Cases, n Fold change P-value (Refs.)
MCM2 110 3.251 3.46×10−13 (33)
116 2.436 3.20×10−17 (34)
66 2.411 2.36×10−6 (35)
246 2.120 3.44×10−11 (36)
107 1.993 7.61×10−11 (37)
39 1.846 6.36×10−5 (38)
96 1.668 4.35×10−6 (39)
MCM3 46 1.992 5.27×10−5 (40)
116 1.617 4.13×10−16 (34)
110 1.591 1.34×10−7 (33)
MCM4 110 3.390 3.60×10−15 (33)
66 2.649 7.09×10−10 (35)
116 2.618 1.36×10−18 (34)
107 2.403 8.50×10−19 (37)
96 1.982 3.80×10−20 (39)
46 1.923 1.02×10−4 (40)
246 1.668 6.17×10−12 (36)
MCM5 46 1.810 4.58×10−6 (40)
110 1.544 1.09×10−8 (33)
MCM6 46 2.932 1.15×10−4 (40)
110 2.114 1.69×10−12 (33)
39 2.012 4.04×10−6 (38)
107 1.830 2.25×10−15 (37)
116 1.797 2.63×10−12 (34)
66 1.760 3.20×10−6 (35)
MCM7 110 4.547 4.11×10−8 (33)
107 1.628 2.08×10−10 (37)
66 1.579 1.72×10−5 (35)
116 1.551 1.24×10−10 (34)
39 1.513 1.60×10−4 (38)
MCM8 110 1.987 1.37×10−8 (33)
MCM10 110 6.446 7.96×10−8 (33)
246 1.792 1.92×10−9 (36)
116 1.733 5.36×10−14 (34)
107 1.509 1.22×10−9 (37)

MCM, minichromosome maintenance; Ref, reference.